Ipsen S.A. – OTC:IPSEY

Ipsen S.A. stock price today

$32.38
+4.12
+14.58%
Financial Health
0
1
2
3
4
5
6
7
8
9

Ipsen S.A. stock price monthly change

-4.78%
month

Ipsen S.A. stock price quarterly change

-4.78%
quarter

Ipsen S.A. stock price yearly change

-4.14%
year

Ipsen S.A. key metrics

Market Cap
8.64B
Enterprise value
8.96B
P/E
10.22
EV/Sales
1.83
EV/EBITDA
5.62
Price/Sales
1.83
Price/Book
2.21
PEG ratio
0.10
EPS
N/A
Revenue
N/A
EBITDA
N/A
Income
N/A
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
17.96%
Oper. margin
26.62%
Gross margin
81.8%
EBIT margin
26.62%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Ipsen S.A. stock price history

Ipsen S.A. stock forecast

Ipsen S.A. financial statements

Ipsen S.A. (OTC:IPSEY): Profit margin
Dec 2022 1.59B 254.3M 15.98%
Jun 2023 1.53B 195.2M 12.7%
Dec 2023 1.59B 449.2M 28.24%
Mar 2024 0 0
Ipsen S.A. (OTC:IPSEY): Analyst Estimates
2025 3.96B 223.26M 5.64%
2026 4.22B 242.90M 5.75%
2027 4.55B 273.23M 6%
2028 4.65B 263.31M 5.65%
  • Analysts Price target

  • Financials & Ratios estimates

1.30%
Yield TTM
Ipsen S.A. (OTC:IPSEY): Payout ratio
Payout ratio 22.75%
Ipsen S.A. (OTC:IPSEY): Dividend Yield
2019 1.27%
2020 1.51%
2021 1.21%
2022 1.2%
2023 4.29%
Ipsen S.A. (OTC:IPSEY): Debt to assets
Jun 2022 5507100000 2.44B 44.32%
Dec 2022 5607900000 2.27B 40.5%
Jun 2023 6090600000 2.68B 44.12%
Dec 2023 6322900000 2.49B 39.52%
Ipsen S.A. (OTC:IPSEY): Cash Flow
Jun 2022 419.8M -178.6M 40.9M
Dec 2022 533.4M -280M -186.9M
Jun 2023 414.8M -986M -195.5M
Dec 2023 428.5M -86.2M -240.3M

Ipsen S.A. alternative data

Ipsen S.A. (OTC:IPSEY): Employee count
Aug 2023 5,072
Sep 2023 5,300
Oct 2023 5,300
Nov 2023 5,300
Dec 2023 5,300
Jan 2024 5,300
Feb 2024 5,300
Mar 2024 5,325
Apr 2024 5,325
May 2024 5,325
Jun 2024 5,325
Jul 2024 5,325

Ipsen S.A. other data

Thursday, 3 October 2024
globenewswire.com
Monday, 23 September 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Friday, 26 July 2024
globenewswire.com
Thursday, 25 July 2024
globenewswire.com
globenewswire.com
Monday, 10 June 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Friday, 5 April 2024
Seeking Alpha
Monday, 25 March 2024
Seeking Alpha
Wednesday, 16 August 2023
Reuters
Thursday, 9 February 2023
Seeking Alpha
Saturday, 30 July 2022
Seeking Alpha
Friday, 11 February 2022
Seeking Alpha
  • What's the price of Ipsen S.A. stock today?

    One share of Ipsen S.A. stock can currently be purchased for approximately $32.38.

  • When is Ipsen S.A.'s next earnings date?

    Unfortunately, Ipsen S.A.'s (IPSEY) next earnings date is currently unknown.

  • Does Ipsen S.A. pay dividends?

    Yes, Ipsen S.A. pays dividends and its trailing 12-month yield is 1.3% with 23% payout ratio. The last Ipsen S.A. stock dividend of undefined was paid on 7 Sep 2025.

  • How much money does Ipsen S.A. make?

    Ipsen S.A. has a market capitalization of 8.64B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.75% to 3.31B US dollars.

  • What is Ipsen S.A.'s stock symbol?

    Ipsen S.A. is traded on the OTC under the ticker symbol "IPSEY".

  • What is Ipsen S.A.'s primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.

  • How do i buy shares of Ipsen S.A.?

    Shares of Ipsen S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Ipsen S.A. have?

    As Jul 2024, Ipsen S.A. employs 5,325 workers.

  • When Ipsen S.A. went public?

    Ipsen S.A. is publicly traded company for more then 15 years since IPO on 8 Jun 2010.

  • What is Ipsen S.A.'s official website?

    The official website for Ipsen S.A. is ipsen.com.

  • How can i contact Ipsen S.A.?

    Ipsen S.A. can be reached via phone at +33 1 58 33 50 00.

Ipsen S.A. company profile:

Ipsen S.A.

ipsen.com
Exchange:

OTC

Full time employees:

5,000

Industry:

Drug Manufacturers—Specialty & Generic

Sector:

Healthcare

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

65, quai Georges Gorse
Boulogne-Billancourt, 92100

:
ISIN: US4626292050
: